• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Aptiv Solutions enables first surrogate endpoint-based adaptive clinical trials

Aptiv Solutions enables first surrogate endpoint-based adaptive clinical trials

March 21, 2014
CenterWatch Staff

Aptiv Solutions, a global biopharmaceutical and medical device development services company, has released ADDPLAN 6.1, the first statistical software to enable the use of surrogate endpoints to expedite interim analysis decisions in adaptive clinical trials. With this tool, survival trials for cancer therapeutics and other trials with long-duration endpoints can now utilize adaptive designs to a far greater extent.

ADDPLAN 6.1 is the latest enhancement to the ADDPLAN family of innovative software for the design, simulation and analysis of adaptive clinical trials. Current ADDPLAN users include industry regulators at the FDA, the EMA and Japan’s Pharmaceuticals Medical Devices Agency (PMDA), more than 50 pharmaceutical and medical device companies and academic researchers.

Surrogate endpoints, which include biomarkers that substitute for a clinical endpoint, are instrumental in the FDA’s commitment to “speeding access to important new therapies.” Drugs that show clinical benefit on certain types of surrogate endpoints can receive a Breakthrough Therapy Designation from the FDA that expedites development and review. As part of its Accelerated Approval program, the FDA may approve drugs for serious conditions with unmet medical needs on the basis of a surrogate endpoint. 

Surrogate endpoints also can be used for interim selection of treatment arms or sub-group selection in population enrichment designs. Specifically, seamless phase II/III adaptive designs often use surrogate endpoint analysis to increase the speed of decision-making. Selecting phase II treatment arms based on a surrogate endpoint can not only accelerate phase II, but also benefit phase III because patients in the treatment arm can continue on to the confirmatory analysis.

“Trials utilizing surrogate endpoint analysis to select treatment arms require a different statistical method than those using the clinical endpoint. ADDPLAN 6.1 is the first software to include the appropriate statistical methods for the use of surrogates in interim analysis decisions,” said Gernot Wassmer, Ph.D., senior vice president and chief software architect at Aptiv Solutions. “ADDPLAN 6.1 is a powerful tool for implementing innovative designs for survival based trials, such as those in oncology or cardiovascular disease, to improve drug development decision-making.”

ADDPLAN 6.1 utilizes a variant of the p-value combination method in a closed test procedure to account for repetition of patients in the exploratory and confirmatory phases. The approach enables the use of surrogates in survival (or time-to-event) designs in both the multiple comparison and the population enrichment settings. As a unique feature, ADDPLAN 6.1 simulates how the use of surrogate versus primary endpoints impacts trial outcomes and operational requirements.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing